2022
DOI: 10.1016/j.amjsurg.2021.07.025
|View full text |Cite
|
Sign up to set email alerts
|

Parathyroid allotransplantation for the treatment of permanent hypoparathyroidism: A systematic review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 8 publications
(10 citation statements)
references
References 39 publications
0
10
0
Order By: Relevance
“…Because of this, we constructed our own success criterion aimed to filter for quality and to promote uniformity in the definition of transplantation success. We hoped this would present a more realistic representation of the treatment efficacy in comparison to other systematic reviews on the same topic that did not set a filter [ 43 , 44 ]. As expected, our calculated success was decreased in respect to that of Kim et al [ 43 ]: we calculated a 47% success rate with a median FU of 24 months as supposed to their 73.3% with a mean FU duration of 18.6 ± 14.3 months for transient immunosuppression, and our 67% success rate with a median FU of 9.5 months as supposed to their 87.5% survival with a median FU of 11.5 months for permanent immunosuppression (Parameswaran et al [ 44 ] had an incomparable outcome).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Because of this, we constructed our own success criterion aimed to filter for quality and to promote uniformity in the definition of transplantation success. We hoped this would present a more realistic representation of the treatment efficacy in comparison to other systematic reviews on the same topic that did not set a filter [ 43 , 44 ]. As expected, our calculated success was decreased in respect to that of Kim et al [ 43 ]: we calculated a 47% success rate with a median FU of 24 months as supposed to their 73.3% with a mean FU duration of 18.6 ± 14.3 months for transient immunosuppression, and our 67% success rate with a median FU of 9.5 months as supposed to their 87.5% survival with a median FU of 11.5 months for permanent immunosuppression (Parameswaran et al [ 44 ] had an incomparable outcome).…”
Section: Discussionmentioning
confidence: 99%
“…We hoped this would present a more realistic representation of the treatment efficacy in comparison to other systematic reviews on the same topic that did not set a filter [ 43 , 44 ]. As expected, our calculated success was decreased in respect to that of Kim et al [ 43 ]: we calculated a 47% success rate with a median FU of 24 months as supposed to their 73.3% with a mean FU duration of 18.6 ± 14.3 months for transient immunosuppression, and our 67% success rate with a median FU of 9.5 months as supposed to their 87.5% survival with a median FU of 11.5 months for permanent immunosuppression (Parameswaran et al [ 44 ] had an incomparable outcome). In summary, the suspected biases combined with the neglect of providing essential information about transplantation characteristics lead to the suspicion of the calculated success rate, most likely still overestimating the true effectiveness of this treatment modality in its current state.…”
Section: Discussionmentioning
confidence: 99%
“…Permanent functional hypoparathyroidism is defined by the need for oral calcium administration to a patient with apparently normal PTH levels (E. Kim, Ramonell, Mayfield, & Lindeman, 2021;Sitges-Serra, 2021). Obiarinze et al, (2021) believes that there may be normalization of parathyroid function up to two years after thyroidectomy (Obiarinze, Fazendin, Iyer, Lindeman, & Chen, 2021).…”
Section: Classification Of Hypocalcemiamentioning
confidence: 99%
“…According to Kim et al, (2021) and others, performing two PTH measurements (intraoperative and immediate postoperative), found that PTH values greater than 10.0 pg/ml and an increase in postoperative PTH compared to intraoperatively indicate low risk of hypocalcemia (Daskalaki et al, 2022;D. H. Kim et al, 2021;Rahman, 2021).…”
Section: Hyperparathyroidismmentioning
confidence: 99%
“…A wide range of case reports and methodologies have been described dating back to the 1950s with relative success. 8,9 The most common source of viable parathyroid tissue for allotransplantation has come from hyperplastic glands of living donor patients with secondary hyperparathyroidism triggered by chronic renal failure. 9 These glands were most often cryopreserved or cultured before transplantation, leading to a large degree of variance in allotransplantation strategies and outcomes.…”
Section: Introductionmentioning
confidence: 99%